A Strong Month For Genomics-Focused Etfs
Canadian ETF Market | Dec 04, 2023 09:44
Genomics is the study of genes and their functions. With technology advancements dramatically improving the cost, accuracy, and time to map a person’s entire genome, many rapidly growing companies are emerging in the genomics sector.
In looking at the recent weekly return data of the BMO (TSX:BMO) ARK Genomic Revolution ETF (TSX:ARKG) (Ticker: ARKG) and iShares Genomics Immunology and Healthcare Index ETF (TSX:XDNA) (Ticker: XDNA), both prominent genomic-focused solutions, their performance in the month of November 2023, thus far, has been above their recent historical averages.
The upswing in returns can be attributed to CRISPR Therapeutics, a biotechnology company focused on developing transformative gene-based treatments for serious diseases using its proprietary CRISPR/Cas9 platform. Recently, U.K. health regulators approved CRISPR’s treatment for sickle cell disease and beta-thalassemia, a therapy called Casgevy. Sickle-cell disease, also known as sickle-cell anemia, can cause debilitating pain, and people with beta-thalassemia often require regular blood transfusions.
Casgevy uses CRISPR/Cas9 to edit a patient's hematopoietic stem cells (HSCs), which are responsible for producing blood cells. The edited HSCs are then infused back into the patient, where they produce functional hemoglobin and reduce or eliminate the need for blood transfusions. If Casgevy is approved in the U.S. and European Union, it has the possibility to be a huge commercial opportunity for CRISPR Therapeutics; this possibility has resulted in increased fervor around the stock and the ETF solutions that are exposed to it.
h2 Investing in Genomic Innovation/h2In recent years, the word innovation has oftentimes become associated with technological advancement, however, healthcare innovation is an area that is also evolving and proving to be filled with long-term investment opportunities. BMO’s ARKG ETF reflects the investment thesis of innovation investor, Cathy Wood of ARK Investment Management. The actively managed solution invests in a cross-section of sectors, including healthcare, information technology, materials, energy, and consumer discretionary that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). Conversely, iShares’XDNA ETF replicates the performance of the NYSE FactSet Global Genomics and Immuno Biopharma Index, which provides exposure to companies poised to benefit from the long-term growth and innovation of companies involved in genomics, immunology, and bioengineering.
Get The App
For investors seeking exposure to companies with long-term growth prospects and that have demonstrated innovative capabilities within the biomedical space, both ARKG and XDNA provide exposure to leading companies in genomics that are poised to shape and advance the medical landscape of the future.
This content was originally published by our partners at the Canadian ETF Marketplace .
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.